Approved indications:

• Treatment of iron deficiency anemia in adults with chronic kidney disease receiving hemodialysis who are also receiving supplemental epoetin.
• Treatment of iron deficiency anemia in pediatric patients 6 years and older with chronic kidney disease receiving hemodialysis and supplemental epoetin.

Off-label uses (evidence level):

• May be used off-label for iron deficiency anemia in other chronic kidney disease settings when intravenous iron is needed and other IV iron products are not suitable; evidence is limited and other formulations (such as iron sucrose or ferric carboxymaltose) are more commonly used.
• Choice among IV iron products is usually based on local protocols, cost, logistics (number and length of infusions), and clinician experience rather than large head-to-head outcome differences.

Efficacy expectations and time course:

• Iron stores typically improve over a course totaling about 1,000 mg of elemental iron given across several hemodialysis sessions.
• Hemoglobin often begins to rise within 2–4 weeks if iron deficiency is the main cause of anemia and epoetin dosing is adequate.
• Clinical benefits usually include higher hemoglobin, less fatigue, and reduced need for blood transfusions, with efficacy broadly comparable to other modern intravenous iron products when equivalent iron doses are given.

Typical dosing and how it is given:

• Adults on hemodialysis: the usual repletion dose is 125 mg elemental iron (10 mL) given intravenously at each dialysis session, often for 8 sessions (total 1,000 mg).
• Children 6 years and older on hemodialysis: a typical dose is 1.5 mg/kg elemental iron (0.12 mL/kg), diluted in 0.9% saline and infused over about 1 hour per dialysis session.
• It is given only by intravenous route, usually diluted in normal saline and infused over at least 1 hour, or as a slow undiluted IV injection during the dialysis session, in a clinical setting with staff able to manage allergic reactions.

Special administration instructions:

• Do not exceed a single dose of 125 mg elemental iron unless specifically directed by a specialist, because higher single doses are linked with more side effects.
• The infusion is typically given during or immediately after hemodialysis, with blood pressure and symptoms monitored during and for a period after the dose.
• The solution should only be mixed with 0.9% sodium chloride for infusion and should not be mixed with other medicines in the same line unless compatibility is known.

Missed doses and overdose:

• If a dose is missed (for example, if a dialysis session is skipped), the dialysis or nephrology team will usually reschedule the infusion; patients should not try to "make up" extra doses on their own.
• Overdose or excessive cumulative dosing can cause iron overload and organ damage; symptoms may include joint pain, fatigue, abdominal pain, or abnormal liver tests.
• In suspected overdose, urgent medical evaluation is needed; treatment focuses on stopping further iron, supportive care, and, if appropriate, iron chelation therapy as directed by specialists.

Common side effects (usually mild to moderate):

• Gastrointestinal symptoms such as nausea, vomiting, or diarrhea.
• Low blood pressure, flushing, dizziness, headache, or muscle cramps during or shortly after the infusion.
• Chest, back, or limb pain, fatigue, fever, or injection-site reactions (pain, swelling, or discoloration).

Serious or rare adverse effects (seek immediate medical care):

• Severe allergic or hypersensitivity reactions, including trouble breathing, wheezing, swelling of the face or throat, severe rash, or collapse.
• Severe drop in blood pressure, loss of consciousness, or chest pain that could signal heart problems.
• Iron overload (too much iron) with repeated or excessive dosing, which can damage organs over time.

Warnings and precautions:

• Should not be used in people with known hypersensitivity to sodium ferric gluconate complex in sucrose or in those with iron overload conditions (such as hemochromatosis) or anemia not caused by iron deficiency.
• Use in pregnancy or breastfeeding is generally considered when the expected benefit (correcting significant iron deficiency) outweighs potential risks; discuss timing and alternatives with the obstetric or pediatric provider.
• Safety and effectiveness are established in children 6 years and older; use in younger children is not well studied.
• Caution is needed in patients with active infections or chronic liver disease, because excess iron can worsen some conditions.

Safety compared with other IV iron products:

• Overall risk of severe allergic reactions is low and similar to other newer IV iron formulations, and lower than with older high–molecular weight iron dextran.
• Because higher single doses are associated with more side effects, this product is usually given in smaller, repeated doses rather than as a single large "total dose" infusion.

Reporting side effects and staying informed:

• Report any side effects to your dialysis team or prescribing clinician, who can adjust treatment and monitoring as needed.
• Side effects can also be reported to the U.S. Food and Drug Administration (FDA) through the MedWatch program or to the drug manufacturer for ongoing safety monitoring.

Drug, supplement, and food interactions:

• There are no major interactions with most commonly used medicines, but any drug that also lowers blood pressure (such as antihypertensives or rapid fluid removal during dialysis) may increase the chance of hypotension when given around the same time.
• Concomitant use with other intravenous iron products is generally avoided except under specialist guidance, to reduce the risk of iron overload and hypersensitivity reactions.
• Oral iron supplements are often reduced or stopped while receiving IV iron, as they add little benefit and may increase gastrointestinal side effects.
• No specific interactions with foods or alcohol are known, but alcohol should be limited in people with liver disease or anemia.

Precautions and situations requiring extra care:

• Do not use in patients with iron overload, certain hereditary iron storage disorders, or anemia not due to iron deficiency.
• Use cautiously in patients with active infections, chronic liver disease, or a history of severe reactions to IV iron; slower infusion rates and closer monitoring may be needed.
• Because benzyl alcohol is an excipient, use in premature infants or neonates is not recommended; safety is established only for children 6 years and older.

Monitoring needs:

• Before and during therapy, clinicians usually monitor hemoglobin, hematocrit, ferritin, and transferrin saturation to confirm iron deficiency and avoid iron overload.
• Blood pressure, heart rate, and symptoms are monitored during and shortly after each dose to detect hypotension or hypersensitivity reactions early.
• Recent IV iron can transiently raise serum iron and transferrin saturation, so iron studies are often checked at least several days after a dose for accurate interpretation.

Q: What is sodium ferric gluconate complex in sucrose used for?
A: It is an intravenous iron medicine used mainly to treat iron deficiency anemia in adults and children 6 years and older who have chronic kidney disease and are receiving hemodialysis plus epoetin.

Q: How long does it take to feel better after starting this medicine?
A: Many people begin to notice improved energy and less shortness of breath within a few weeks, as hemoglobin levels gradually rise with a full course of treatment.

Q: How is this drug different from taking iron pills?
A: It delivers iron directly into the bloodstream, which bypasses the gut, works more reliably in people with kidney disease, and avoids many stomach side effects that occur with oral iron tablets.

Q: Can I receive this medicine if I am pregnant or breastfeeding?
A: It may be used during pregnancy or breastfeeding when the benefits of correcting significant iron deficiency outweigh potential risks, but the decision and timing should be made together with your kidney and obstetric or pediatric care teams.

Q: What should I watch for during and after the infusion?
A: Tell the nurse or doctor right away if you feel dizzy, short of breath, have chest pain, itching, rash, or swelling of the face or throat, as these can be signs of low blood pressure or an allergic reaction that need immediate attention.